<DOC>
	<DOCNO>NCT02639637</DOCNO>
	<brief_summary>The purpose study understand dipeptidyl peptidase IV ( DPP4 ) inhibition diabetic affect hemodynamic parameter sympathetic activation set increase concentration neuropeptide Y , endogenous peptide . The central hypothesis DPP4 inhibition decrease degradation neuropeptide Y , result increase vasoconstriction sympathetic activation .</brief_summary>
	<brief_title>Effect DPP4 Inhibition Vasoconstriction</brief_title>
	<detailed_description>Dipeptidyl peptidase IV ( DPP4 ) inhibitor routinely use treatment type II diabetes mellitus ( T2DM ) . Since prevalence hypertension 1.5-3 time great diabetic compare sex-aged matched control , use antihypertensive ACE inhibitor also common diabetic . DPP4 involved degradation multiple vasoactive peptide , one neuropeptide Y . This peptide think play role blood pressure regulation sympathetic nervous system activation . The aim study investigate DPP4 inhibition affect vasoconstriction response increase neuropeptide Y concentration . Additionally , investigator want understand combination DPP4 inhibition ACE inhibition affect vasoconstriction sympathetic activation . Understanding hemodynamic neurohumoral change associate DPP4 ACE inhibitor important implication million patient T2DM take drug concurrently .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Type 2 Diabetes Mellitus , define one following , Hgb A1C ≥6.5 % , Fasting plasma glucose ≥126mg/dL , Two hour plasma glucose ≥200 mg/dL follow 75gr oral glucose load For female subject follow condition must meet : Postmenopausal status least 1 year , Status postsurgical sterilization , If childbearing potential , utilization form birth control willingness undergo βHCG test prior drug treatment every study day Type 1 diabetes . Poorly control T2DM , define Hgb A1C &gt; 8.7 % . Use antidiabetic medication metformin . Hypertension . Subjects participated weightreduction program last 6 month whose weight increase decreased 5 kg precede 6 month . Pregnancy . Breastfeeding . Treatment follow drug : cisapride , pimozide , terfenadine , astemizol Clinically significant gastrointestinal impairment could interfere drug absorption Cardiovascular disease would pose risk subject participate study , : myocardial infarction within 6 month prior enrollment , presence angina pectoris , significant arrhythmia , congestive heart failure ( LV hypertrophy acceptable ) , deep vein thrombosis , pulmonary embolism , second thirddegree AV block , mitral valve stenosis , hypertrophic cardiomyopathy . Impaired hepatic function ( aspartate amino transaminase [ AST ] and/or alanine amino transaminase [ ALT ] &gt; 2 x upper limit normal range ) Impaired renal function ( eGFR &lt; 60mL/min/1.73m2 determine MDRD equation ) . History presence immunological hematological disorder . History pancreatitis know pancreatic lesion . History angioedema cough take ACE inhibitor . Hematocrit &lt; 35 % . Treatment anticoagulant . Growth hormone deficiency . Diagnosis asthma require use inhale β2 agonist 1 time per week . Any underlying acute disease require regular medication could possibly pose threat subject make implementation protocol interpretation study result difficult Treatment systemic glucocorticoid within last 6 month . Treatment lithium salt Ongoing tobacco use recreational drug use . Treatment investigational drug 1 month precede study Mental condition render subject unable understand nature , scope , possible consequence study Inability comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Sitagliptin</keyword>
	<keyword>Dipeptidyl Peptidase IV Inhibitors</keyword>
	<keyword>Angiotensin Converting Enzyme Inhibitors</keyword>
	<keyword>Enalaprilat</keyword>
	<keyword>Neuropeptide Y</keyword>
</DOC>